{"id":419,"date":"2024-02-14T19:21:03","date_gmt":"2024-02-14T19:21:03","guid":{"rendered":"https:\/\/www.merckvaccines.com\/capvaxive\/?page_id=419"},"modified":"2026-03-26T09:19:42","modified_gmt":"2026-03-26T09:19:42","slug":"ipd-case-coverage","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/capvaxive\/ipd-case-coverage\/","title":{"rendered":"IPD Case Coverage of CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine)"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
\n\n
<\/div>\"\"
Actor Portrayal<\/div><\/div><\/picture>

IPD case coverage for adults<\/mark><\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n\n

Serotypes covered by CAPVAXIVE vs PCV20<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

CAPVAXIVE is the only FDA-approved PCV that helps protect against serotypes responsible for ~82% of IPD cases in adults 50 years or older, compared to ~54% by PCV20 at a national level.1,2,a<\/sup><\/p><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n

Proportion of IPD Coverage by CAPVAXIVE and PCV20 serotypes in adults aged \u226550 years at a national level, 2019-20231,2,a<\/sup><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n\n
\"%\"%<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n
\"\"\"\"<\/figure><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

CAPVAXIVE, non-PCV20 serotypes:<\/strong> 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, 35B1<\/sup>
Shared serotypes:<\/strong> 3, 6A, 7F, 8, 10A, 11A, 12F, 15B, 19A, 22F, 33F
PCV20, non-CAPVAXIVE serotypes:<\/strong> 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F<\/p><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

In certain adult populations in Alaska, Colorado, New Mexico, Oregon, and the Navajo Nation, a higher prevalence of IPD caused by serotype 4, which is not included in CAPVAXIVE, has been reported. IPD surveillance from other geographic areas in the US has not detected significant percentages of serotype 4.3<\/sup><\/p><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

Intentional serotype selection<\/strong>1,2,b<\/sup><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

CAPVAXIVE is specifically designed to help protect against the serotypes responsible for the most cases of adult IPD.<\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

11 serotypes in CAPVAXIVE<\/strong><\/mark>
that are not covered by PCV20 cause
~37% of IPD cases<\/strong><\/mark>
in adults 50 years or older at a national level.<\/p><\/div><\/div>\n<\/div>\n\n\n\n

\n
\"\"\"\"<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n

9 serotypes in PCV20<\/strong>
that are not covered by CAPVAXIVE cause
~8% of IPD cases<\/strong>
in the same age group.<\/p><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines.2<\/sup> There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20.<\/p><\/div><\/div>\n\n\n\n

\n
<\/div>\n\n\n\n

Serotypes included in CAPVAXIVE vs other pneumococcal vaccines<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

CAPVAXIVE includes 8 unique serotypes that are not included in any other pneumococcal vaccine. These 8 unique serotypes are responsible for ~25% of IPD cases in adults 50 years of age or older at a national level.1,2,a,c<\/sup><\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n

The 8 unique serotypes in CAPVAXIVE are responsible for ~25% of IPD cases in adults 50 years or older at a national level1,2,a<\/sup><\/h2><\/div>\n\n\n\n
\"Serotypes<\/figure><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines.2<\/sup> There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20.<\/p><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n\n
\"\"\/<\/picture><\/figure><\/div>

How was CAPVAXIVE studied?<\/mark><\/h2>
\n\n

Learn about the robust Phase 3 clinical trial program and the immune responses observed.<\/p>\n\n\n

\n\n\n\n
View clinical studies<\/a><\/div>\n\n<\/div>\n\n\n
<\/div>\n\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n\n
\n\n
\n
<\/div>\n\n\n\n